Navigation Links
New International Pharmaceutical Company Pro Bono Bio Launched Today
Date:9/11/2011

ike Flexiseq™, these new products are based on Pro Bono Bio's innovative Sequessome Technology™, which is able to physically absorb (sequester) and remove chemicals that are a key component in the pain and inflammation cascade.

Sequessomes were invented and developed by Pro Bono Bio executives in conjunction with external collaborators. This exciting new technology is covered by several global patents owned by Pro Bono Bio. The development of Flexiseq™ is one of many examples of how Pro Bono Bio successfully collaborates with external parties to discover and develop new products.

Pro Bono Bio's other pipeline products include blood factors for the treatment of haemophilia as well as novel antibiotics for the treatment of serious infections such as C.difficile, MRSA and Tuberculosis. Pro Bono Bio plans to develop and commercialise this innovative pipeline by capitalising on its management team's Big Pharma experience.

John Mayo, CEO of Pro Bono Bio, said "Pro Bono Bio is an ambitious new international pharmaceutical company which expects to make a real difference to healthcare on a global scale. With an exciting pipeline of products and an innovative business model we intend to ensure that Pro Bono Bio can deliver attractive shareholder returns while at the same time making a growing contribution to healthcare budgets in areas such as The East African Community where resources are extremely limited."

Pro Bono Bio will initially focus the marketing of Flexiseq and the other products based on its Sequessome Technology™ in Western, Central and Eastern Europe as well as the CIS. Pro Bono Bio's commercial and manufacturing model involves collaboration with specialist service partners.  The outsourced sales model will be supplemented in coming years with selective full ownership of the sales force in certain territories.  Similarly, Pro Bono Bio's products will initially be sourced from Euro
'/>"/>

SOURCE Pro Bono Bio
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force
2. VWR International, LLC Acquires INTERNATIONAL P.B.I. S.p.A.
3. Bench International Expands Presence in Europe with Opening of Offices in Switzerland
4. Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
5. Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients
6. Chindex International, Inc. Announces Participation in Upcoming Investor Conferences
7. Pharmaceutics International, Inc. (Pii) Successfully Completes EMA and FDA Inspection
8. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
9. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
10. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
11. Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  InnoPharma, Inc. today ... 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  ... and disturbed behaviors in patients with schizophrenia or bipolar ... generic injectable drug, InnoPharma has entered into an agreement ... Canada will make, use, sell, market and distribute ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ... non-invasive and minimally invasive applications, today announced that the Board ... and Chief Financial Officer Timothy W. Baker to ... will continue to serve as CFO and will take the ... Chairman and Chief Executive Officer. "Tim has ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014 /PRNewswire/ ... ) announced today that an article based on post-hoc analyses ... "Early Weight Loss While on Lorcaserin, Diet, and Exercise as ... in the online issue of Obesity , the official ... these analyses was to identify whether there is an early ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mass., Nov. 17 Decision Resources, one of the world,s ... finds that, driven by the continued dominance of opioids that ... cancer pain drug market will increase from $2.3 billion in ... France, Germany, Italy, Spain, the United Kingdom and Japan. , ...
... , DURHAM, N.C., Nov. 17 Oxygen ... the company has begun shipping Dermacyte(TM) Oxygen Concentrate Gel ... The shipments, which are going out today, cover orders ... milestone event for our company - actually shipping a ...
Cached Medicine Technology:The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018 2Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... 30, 2014 Hamilton Facial Plastic ... its new Carmel office on July 30th. After months ... be moving to the state-of-the-art suite, located only steps ... space will allow for one-on-one patient comfort, shorter wait ... , Dr. Hamilton’s new office-suite will continue to ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
(Date:7/30/2014)... Over 630 doctors worldwide are now certified ... minimally invasive treatment for gum recession. Santa Barbara, CA ... peers to be the “father of microsurgery” in periodontics ... Pinhole Surgical Technique® training course at the Chao Pinhole ... of the American Academy of Periodontics (AAP) 2010 Master ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Children’s Hospital ... celebrate Safety Day from 4 p.m. to 7 p.m. ... (29580 7 Mile Road, Livonia, MI 48152). The event ... bike helmets, children’s activities, music, snacks and local public ... to the Children’s Hospital of Michigan Foundation. , ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... guidelines show half to two-thirds of women of childbearing ... News) -- A new study says federal guidelines on ... the category of "obese." , U.S. guidelines determine who ... whether a person,s height and weight are proportional. The ...
... much control a person has over their own health outcomes. ... when doctor and patient attitudes on the issue match up, ... Published online and in the May issue of the ... of a growing body of evidence indicating that patient-physician compatibility ...
... fewer side effects, experts say, , WEDNESDAY, April 21 (HealthDay ... promise in early testing as a possible new treatment for ... It,s too early to tell if the drug actually works, ... federal approval to be prescribed to patients. Still, the drug ...
... power, according to Penn State researchers who will test ... to help them manage their disease. The project, ... Chris Sciamanna, professor, department of medicine, Penn State College ... Lung and Blood Institute as part of the National ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... D.C. Women who have a breast density of 75 ... breast cancer that is four to five times greater than ... breast density one of the strongest biomarkers of breast cancer ... 101st Annual Meeting 2010, held in Washington, D.C., April 17-21, ...
Cached Medicine News:Health News:More U.S. Women May Be Obese Than Thought 2Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Knowledge is power in Penn State blood pressure study 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:Mammographic density and risk of breast cancer 2Health News:Mammographic density and risk of breast cancer 3Health News:Mammographic density and risk of breast cancer 4Health News:Mammographic density and risk of breast cancer 5
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: